SkyePharma PLC (SKYE) Announces Positive Phase III Data on FlutiformTM
More News related to SKYE
- SkyePharma PLC -- Interim Results
- Skyepharma PLC announces Research Update
- Jefferies & Co Downgrades SkyePharma (SKYE) to Underperform
- Skyepharma PLC announces Trading Update
- SkyePharma PLC (SKYE) Announces Positive Phase III Data on FlutiformTM
More News related to FDA
- Orthofix International (OFIX) Receives FDA 510(k) Approval
- Rosetta Genomics (ROSG) Identifies Potential microRNA Biomarkers in Blood Serum
- BioCryst Pharma (BCRX) Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis
- Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
- GTC Biotherapeutics (GTCB) Granted Priority Review from the FDA
SkyePharma PLC (Nasdaq: SKYE) announces that its third Phase III efficacy study evaluating FlutiformTM for the treatment of mild to moderate asthma in adolescent and adult patients has met its primary endpoints.
Related Categories
FDAStocks Mentioned
-0.56Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
